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Abstract
The MEK–ERK growth signaling pathway is important
in human hepatocellular carcinoma (HCC). To evaluate
the targeting of this pathway in HCC, we characterized
a novel, orally-active MEK inhibitor, PD184161, using
human HCC cells (HepG2, Hep3B, PLC, and SKHep) and
in vivohuman tumor xenografts. PD184161 inhibitedMEK
activity (IC50 = 10–100 nM) in a time- and concentration-
dependent manner more effectively than PD098059 or
U0126. PD184161 inhibited cell proliferation and induced
apoptosis at concentrations of –> 1.0 MM in a time- and
concentration-dependent manner. In vivo, tumor xeno-
graftP-ERKlevelsweresignificantly reduced3 to12hours
after an oral dose of PD184161 (P < .05). Contrarily, tumor
xenograft P-ERK levels following long-term (24 days)
daily dosingof PD184161were refractory to this signaling
effect. PD184161 significantly suppressed tumor engraft-
ment and initial growth (P < .0001); however, established
tumors were not significantly affected. In conclusion,
PD184161hasantitumoreffects inHCC in vitroand in vivo
that appear to correlate with suppression of MEK activity.
These studies demonstrate that PD184161 is unable to
suppressMEKactivity inHCCxenografts in the long term.
Thus, we speculate that the degree of success of MEK-
targeted treatment in HCC and other cancersmay, in part,
depend on the discovery of mechanisms governing MEK
inhibitor signaling resistance.
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Introduction
One of the most common causes of solid organ cancer mor-
tality worldwide is hepatocellular carcinoma (HCC) [1,2]. Al-
though HCC is historically an uncommon malignancy in the
United States, its incidence has been rapidly increasing in
the last decade [1]. At present, the most successful treat-
ment is surgical resection and/or transplantation, which can
only be performed in a very select group of patients [3].
Current nonsurgical treatment strategies that have demonstrat-
ed some effectiveness in selected patients include chemo-
embolization, radiofrequency ablation, percutaneous ethanol
injection, and, occasionally, systemic chemotherapeutics [4].
For most patients, there are no successful treatments available.
Treatment advances have been stalled, in part, by a poor
understanding of the molecular pathogenesis of HCC. Multiple
etiologies of HCC, including aflatoxin B1, hepatitis B virus,
hepatitis C virus, and cirrhosis, alsomake the study ofmolecular
pathogenesis challenging [5]. Nonetheless, most HCCs are
linked to a common pathway of hepatocyte necrosis followed
by rapid proliferation. This process results in genetic or epige-
netic changes, which can lead to the disinhibition and/or over-
expression of growth and survival signaling pathways [6,7].
The extracellular signal–regulated mitogen-activated pro-
tein kinase (p42/p44 MAPK) pathway plays an integral role in
coordinating growth and survival signaling and may play an
important role in the development and progression of HCC.
Extracellular signal–related kinase (ERK) is the terminal ki-
nase in this pathway. ERK has two isoforms, ERK1 and ERK2
(or ERK1,2), which are proline-directed serine/threonine pro-
tein kinases activated by dual phosphorylation on both tyrosine
and threonine residues [8]. During phosphorylation cascade,
ERK1,2 are activated by MAPK kinases (i.e., MEK1,2), which
are in turn activated through the phosphorylation of two serine
residues by serine/threonine kinases such as MEK kinase or
Raf [9,10]. Mitogen-stimulated cell growth, through survival/
apoptosis and cell cycle control, is frequently linked to phos-
phorylated ERK’s translocation from the cytoplasm to the
nucleus and to the initiation of transcriptional activation of cell
regulatory genes [11–13]. The activation of p42/p44 MAPK
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pathway intermediates is sufficient to transform cells, such
as NIH3T3 cells [14]. Similarly,Rasmutations resulting in the
constitutive activation of the p42/p44 MAPK pathway also
cause oncogenic transformation [15].
An observed increase in the expression and activity of
many p42/p44 MAPK signaling intermediates ex vivo in
human HCC tissues has been demonstrated in our labora-
tory as well as in others [16–20]. Additionally, the functional
pathways of p42/p44 MAPK signaling and the importance of
the p42/p44 MAPK pathway signaling in experimental HCC
have also been documented [18,19,21–25]. The activation
and overexpression of members of the p42/p44 MAPK cas-
cade in HCC do not appear to be dependent on Ras or B-Raf
mutations, as these genes are not typically mutated in HCC
[26–28]. However, activated Raf-1 has been shown to be
overexpressed in human HCC [29]. Importantly, EGFR and
transforming growth factor-a are upregulated in HCC, both
of which lead to downstream activation of p42/p44 MAPK
members [30–32]. Finally, alterations in guanine nucleotide
regulatory proteins [25]—and, more recently, viral proteins
from the two most common etiologies of HCC, hepatitis B
and hepatitis C—have been shown to activate the p42/p44
MAPK pathway [33,34].
These data have fueled significant research aimed at
members of the p42/p44 MAPK cascade as potential phar-
macotherapeutic targets [35–37]. To that end, small molecule
inhibitors that target MEK (e.g., PD098059 and U0126) have
been identified in drug discovery programs and have pro-
vided researchers with the means of elucidating of the role of
p42/p44 MAPK signaling in cellular function [38]. The follow-
ing study is an investigation of the efficacy of a novel, orally
active MEK inhibitor PD184161 on human HCC in vitro and
in vivo for the purpose of characterizing its therapeutic po-
tential in experimental HCCand, ultimately, in human disease.
Materials and Methods
Cell Culture
HepG2, Hep3B, PLC, and SKHep cells were obtained
from the American Type Culture Collection (Bethesda, MD).
Adherent cells underwent media changes three times per
week and were maintained in 5% CO2 at 37jC in modified
Eagle’s medium-alpha (10% fetal bovine serum, 100 U/ml
penicillin, and 100 mg/ml streptomycin). Commercially avail-
ableMEK inhibitors PD098059 andU0126 (CalBiochem, San
Diego, CA) as well as PD184161 were used (Pfizer, Ann
Arbor, MI). TheseMEK inhibitors were administered 24 hours
after HCC cells were plated for indicated time periods.
Proliferation Assays and Cell Counts
Cellular proliferation rates were determined using the
colorimetric assayCellTiter 96 AQueous OneSolution Cell Pro-
liferation Assay (Promega, Madison, WI), in which a tetrazo-
lium compound is bioreduced by cells into a colored formazan
product that is soluble in tissue culturemedium. The assaywas
performed according to manufacturer’s protocol and using
methods previously described [39]. Relative cellular growth
(expressed as a percentage) was determined by the ratio of
the average absorbance of treatment wells to the average
absorbance of control wells. Results were confirmed using try-
pan blue–excluded cell counts. Statistical analyses were per-
formed using t-test and one-way analysis of variance (ANOVA)
with Tukey post hoc test.
Apoptosis Assay
Apoptosis was measured using Cell Death Detection DNA
Fragmentation ELISA Kit (Roche Diagnostics, Indianapolis,
IN), which allows for quantitative determination of the amount
of cytoplasmic histone–associated DNA fragments induced by
cells undergoing apoptosis. Cells were plated in 96-well plates
(1  104 cells) and then treated for 48 hours with PD184161
(1–20 mM). The assay was conducted according to the manu-
facturer’s protocol andusingmethodspreviously described [39].
Western Blot Analysis
Cells were lysed in radioimmune precipitation buffer
[phosphate-buffered saline (PBS), 1%Nonidet P-40, 0.5%so-
diumdeoxycholate,0.1%sodiumdodecyl sulfate (SDS),1mM
phenylmethylsulfonyl fluoride, 10 mg/ml aprotinin, and 1 mM
sodium vanadate (Na3VO4)]. Cell lysates were centrifuged
at 10,000 rpm for 10 minutes. Supernatants (10 mg of total
protein) were then resolved by SDS polyacrylamide gel elec-
trophoresis on 4% to 20% gradient gels (Invitrogen, Carlsbad,
CA). Separated proteins were transferred to Immobilon P
membranes (Millipore, Bedford,MA) then incubated for 1 hour
in blocking solution [Tris-buffered saline (TBS), 0.05%Tween,
and 5% nonfat dry milk]. Membranes were washed in TBS
Tween and incubated with primary antibody according to the
manufacturer’s recommendations. After washing with TBS
Tween, they were incubated with appropriate secondary anti-
body solution (horseradish peroxidase–conjugated IgG) for
60 minutes at room temperature. Membranes were washed
again with TBS Tween prior to detection using enhanced
chemiluminescence detection system (Amersham Pharmacia
Biotech, Piscataway, NJ). Primary antibodies employed in-
cluded specific phospho-p42/44 MAP kinase (Thr202/Tyr204)
antibody (Cell Signaling, Beverly, MA) and total ERK1/2 (K-23)
antibody (Santa Cruz Biotech, Santa Cruz, CA). All Western
blot analyses displayed in this manuscript were stripped of
their antibodies and reprobed with actin (c-11) (Santa Cruz
Biotech) to confirm equal protein loading (data not shown).
Densitometric analysis, when applied, was performed using
a Hewlett-Packard (Palo Alto, CA) scanner and analyzed with
Totallab software (Nonlinear Dynamics; Biodynamics, Dur-
ham, NC). Statistical methods (t-test; one-way ANOVA, and
Tukey post hoc test) were applied to densitometric data.
Tumor Xenograft Model
BALB/c athymic nude mice were inoculated with 3 to
5 million freshly isolated Hep3B, SKHep, or PLC cells. Prior
to inoculation, the cells were washed with PBS, trypsinized,
collected, and washed three times with PBS after being pel-
leted (500 rpm). Cells were resuspended in sterile saline and
injected subcutaneously into the right flank of athymic nude
mice. Inoculated animals were then subjected to one of three
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protocols. The inoculatedanimals in protocol 1weremonitored
until the tumors had reached 100 mm3, after which the ani-
mals were treated (by orogastric gavage) with PD184161 or
vehicle (10% ethanol, 10% cremophor EL, and 80%H2O) and
sacrificed 3 hours after treatment. In protocol 2, PD184161
(300 mg/kg) or vehicle was administered twice daily by oro-
gastric gavage for a total of 6 weeks, beginning 12 hours after
HCC cell inoculation. Inoculated animals in protocol 3 were
monitored until the tumors had reached 100 mm3, after which
treatment with PD184161 (300 mg/kg, twice daily, by orogas-
tric gavage) or vehicle was begun and continued for 24 days,
during which time tumors were measured every 3 days. The
animalswere sacrificed, and the tumorswere removed3 hours
after the last treatment with PD184161. Necrotic portions of
tumors, when present, were not used to create tumor homoge-
nates for the analysis of MAPK signaling end points. Statistical
analyses, including t-test and one-way ANOVA, were applied
to tumor growth results from each protocol (P < .05). All an-
imals received humane care according to the criteria outlined
in the ‘‘Guide for the Care and Use of Laboratory Animals’’
prepared by the National Academy of Sciences and published
by the National Institutes of Health (NIH publication 86-23,
revised 1985).
Results
Specificity of PD184161
As reflected by 50% inhibitory concentration (IC50)
values >10 mM, PD184161 (structure shown in Figure 1) did
not inhibit the enzymatic activity of a diverse array of kinases,
comprising a panel of 27 various tyrosine andserine/threonine
kinases (Table 1). Experiments showed that the compound
directly inhibits MEK with an IC50 = 10 to 100 nM. Kinetic
experiments performed indicate that this compound is not
competitive with ATP or theMAPK site onMEK (C.Omer, per-
sonal communication).
Effects of PD098059, U0126, and PD184161 on ERK
Phosphorylation in HCC Cells
For purposes of comparison, the effects of the selective
MEK inhibitors U0126 [40] and PD098059 [41] and the novel
MEK inhibitor PD184161 on MEK activity were examined
in four human HCC cell lines (Hep3B, HepG2, PLC, and
SKHep). Phosphorylated-ERK level was evaluated by ex-
amining the phosphorylation status of ERK1,2, which are sub-
strates of MEK. Immunoblots in Figure 2 demonstrate the
level of ERK1,2 phosphorylation after 1 hour of treatment
with the indicated MEK inhibitors (PD098059, U0126, and
PD184161) at concentrations of 0.1 and 1.0 mM. Of the three
inhibitors, PD184161 proved to be the most effective inhibitor
of ERK1,2 phosphorylation in all four cell lines, as evidenced
by complete inhibition of phosphorylation at 1.0 mM. No
changes were found in total ERK1,2 expression as a result
of any treatment. HepG2 cells were most sensitive to all
MEK inhibitor treatments showing the absence ofMEKactivity,
as demonstrated by phospho-ERK1,2 immunoblot, whereas
Hep3B and SKHep cells were relatively more resistant.
Effect of MEK Inhibition on HCC Cellular Proliferation
To determine the effects of PD184161 on HCC growth,
four human HCC cell lines were treated with varying concen-
trations of PD184161 (1.0–20 mM) for 24, 48, or 72 hours.
Figure 3 depicts the results of a colorimetric proliferation
assay following PD184161 treatment of Hep3B, HepG2,
PLC, andSKHep cells. All cell lines examined exhibited a time-
and concentration-dependent reduction in proliferation after
Figure 1. Chemical structure of PD184161 and PD184352.
Figure 2. Representative Western immunoblots of phosphorylated ERK1,2
and total ERK1,2 proteins from lysates of human HCC cell lines following
treatment with PD098059, U0126, and PD184161. Actively dividing cells
(Hep3B, HepG2, PLC, and SKHep) were treated for 1 hour with one of the
followingmitogen-activated protein kinase kinase (MEK) inhibitors: PD098059,
U0126, or PD184161 (0.1 and 1.0 M). Following treatment, the cells were
lysed, and Western immunoblots were performed using antibodies to phos-
phorylated ERK1,2 (A) and total ERK1,2 (B). Similar results were obtained in
at least two independent experiments.
Table 1. PD184161 Has an IC50 of > 10MM against the following Kinases.
AMPK GSK3b PDK1 S6K1
CDK2/cyclin A JNK/SAPK1c Phos. kinase SAPK2a/p38
CHK1 Lck PKA SAPK2b/p38b2
CK1 MAPKAP-K1a PKBph SAPK3/p38d
CK2 MAPKAP-K2 PKCa SAPK4/p38d
CKS MAPK2/ERK2 PP2a SGK
DYRK1a MSK1 ROCK-II
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treatmentwith PD184161. Aswas the casewith suppression of
phosphorylated ERK1,2 levels, HepG2 cells proved to bemost
sensitive to antiproliferative treatment with this compound. Ef-
fects were observed at all concentrations of PD184161 and at
all time points examined inHepG2cells, whereasHep3B, PLC,
and SKHep cells exhibited significant growth reduction at
higher concentrations.
Effect of MEK Inhibition on Apoptosis in Human HCC Cells
To determine if the antiproliferative effects of PD184161
involve apoptosis as a mechanism, we used DNA fragmen-
tation ELISA to quantify apoptosis. Previous MEK inhibitor
studies have demonstrated that significant effects in apopto-
sis may be observed as early as 48 hours into treatment [39].
Figure 4 shows the effects of PD184161 (1–20 mM) on the
degree of apoptosis in Hep3B, HepG2, PLC, and SKHep
cells 48 hours into treatment. All cell lines showed increases
in apoptosis as a result of PD184161 treatment. HepG2 cells
were most sensitive to PD184161, with >1000% increase in
relative apoptosis at low-dose PD184161 (1 mM). Interest-
ingly, Hep3B cells were more sensitive to higher-dose
PD184161 (10–20 mM) than HepG2 cells, increasing their
apoptosis to >2400%. In contrast, SKHep and PLC cells may
have less apoptosis at low concentrations of PD184161 and
less increases (100–500%) at higher doses (5–20 mM).
Effect of MEK Inhibition on Human HCC Engraftment
and Early Tumor Growth
To determine the effect of PD184161 on human HCC en-
graftment and early tumor growth, we employed the MEK
inhibitor PD184161 in an in vivo human tumor xenograft
model. Fourteen athymic nude mice were inoculated with
Hep3B cells (randomly assigned to two groups of seven)
and, 12 hours later, were dosed by orogastric gavage twice
daily with either 300 mg/kg PD184161 or vehicle for 38 days.
Twice-daily dosing was based on previous studies dem-
onstrating significant P-ERK reduction 1 to 12 hours after dos-
ing (data not shown). Tumor growth was monitored for the
duration of the study, and measurements were taken every
3 days. As shown in Figure 5, treatment with PD184161
resulted in a significant delay in tumor formation (9 days)
relative to the controls. In addition, early tumor growth was
significantly decreased in treated animals. The time required
for tumors to reach 50 mg in size was 38 vs 25 days, in the
treated and control groups, respectively. Using the same
protocol, a separate evaluation of PD184161 treatment in
Figure 3. The effect of the MEK inhibitor PD184161 on the proliferation of four human HCC cell lines (Hep3B, HepG2, PLC, and SKHep). Actively dividing cells
were treated for 24, 48, or 72 hours with concentrations of PD184161 varying from 1.0 to 20 M. A colorimetric proliferation assay was used to determine
proliferation relative to control dimethyl sulfoxide– treated cells. Data are expressed as percentage of control. Each point on the graph represents the mean of
triplicate samples, and error bars represent SEM. Similar results were obtained in at least two independent experiments.
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humanC26 colon adenocarcinoma xenografts also resulted in
a significant delay in tumor formation (6 days) and early tumor
growth rate (data not shown). Metastatic colon cancer is
relevant insofar as it is the most common secondary tumor
of the liver. Therewere no significant differences inweight gain
or loss as a result of any treatment (data not shown). No
treatment-related deaths or toxicity were associated with
PD184161 treatment.
Effect of MEK Inhibition on Established Human
HCC Tumor Growth
Having established an effect of MEK inhibition on tumor
engraftment and early tumor growth, we examined the ef-
fects of PD184161 on established tumors. Fourteen athymic
nude mice were inoculated with Hep3B cells, mice were ran-
domly assigned to two groups of seven, and treatment with
PD184161 (300 mg/kg, twice daily) or vehicle was initiated
when the tumors had reached 100 mm3 and continued for
24 days. No significant difference was detected in tumor
growth in animals treated with PD184161 (P = .17) (Figure 6).
There were no significant differences in weight gain or loss
as a result of any treatment (data not shown). Using the same
protocol, we examined the effects of PD184161 on established
SKHep and PLC tumors. As in Hep3B tumors, PD184161 did
not significantly decrease tumor growth (data not shown).
Effect of PD184161 on MEK Activity in Human
Tumor Xenografts
The early effects of PD184161 in inhibiting tumor engraft-
ment and early growth contrast sharply with the effects of
PD184161 in established tumors. To evaluate the effects of
PD184161 treatment on the phosphorylation status of ERK
in HCC tumors in vivo, Hep3B cells were inoculated into the
flanks of 28 nude mice and the tumors were allowed to grow
up to 100mm3. At this point, half of themicewere dosed orally
with 300 mg/kg PD184161 or vehicle. Fourteen animals were
sacrificed 3 hours after the first dose, whereas 14 others were
treated with 300 mg/kg PD184161 or vehicle twice daily for
24 days and then sacrificed 3 hours after the last treatment.
MEK activity, as measured by phosphorylated ERK1,2, was
significantly decreased in tumors in animals treated with a
single dose of PD184161 compared to controls (Figure 7).
Densitometric analysis revealed a statistically significant 80%
decrease in phosphorylated ERK1,2 levels in tumors from
treated animals (P < .05). Similar results were demonstrated
in C26 human colon adenocarcinoma tumor xenografts (data
not shown). In contrast, phosphorylated ERK1,2 levels were
no longer decreased in HCC tumor xenografts from animals
that underwent treatment for 24 days, suggesting that tumors
become refractory to the effects of PD184161 on MEK activity
(i.e., P-ERK level). To exclude a generalized effect of the
drug or its bioavailability, phosphorylated ERK1,2 levels were
assessed in lung tissues from these same animals (baseline
levels of phosphorylated ERK1,2 in normal liver were barely
detectable, making comparisons of treated group to control
group not feasible). Analysis of lung tissues from treated ani-
mals showed suppression of phosphorylated ERK1,2 levels,
indicating that the drug was still active in vivo. These data
suggest that signaling resistance to MEK inhibition with
PD184161 occurs in the long-term treatment of established
Figure 4. The effect of the MEK inhibitor PD184161 on apoptosis in four
human HCC cell lines (Hep3B, HepG2, PLC and SKHep). Actively dividing
cells were treated for 48 hours with concentrations of PD184161 varying from
1.0 to 20 M. A DNA fragmentation ELISA assay was used to determine
apoptosis relative to control dimethyl sulfoxide– treated cells. Data are ex-
pressed as the percentage of control. Each point on the graph represents the
mean of triplicate samples, and error bars represent SD. Similar results were
obtained in at least two independent experiments.
Figure 5. The effect of twice-daily oral dosing with the MEK inhibitor
PD184161 on the growth of newly inoculated Hep3B tumor xenografts in
nude mice (n = 7). Mice were treated with PD184161 (300 mg/kg) beginning
12 hours after Hep3B inoculation and continued for 38 days. Tumors were
measured every 3 days, and volumes are represented in the figure (E
vehicle; n PD184161). Tumor measurements in PD184161-treated animals
were found to be statistically significant from control at all time points shown
(t-test; P < .05).
Figure 6. The effect of twice-daily oral dosing with the MEK inhibitor
PD184161 on the growth of established Hep3B tumor xenografts in nude
mice (n = 7). Nude mice were inoculated in the flank with 3 to 5 million Hep3B
cells. Once the tumors had reached 100 mm3, the mice were dosed orally
with 300 mg/kg twice daily for 24 days. Tumor measurements were taken
every 3 days, and tumor volume is represented in the figure (E vehicle; n
PD184161). There was no statistically significant difference between treat-
ment groups (P = .17).
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tumors. Nogross or histologic lung pathologywas observed as
a result of PD184161 treatment.
Discussion
The effects of a number of growth and survival signals are
mediated by p42/p44 MAPK signaling [37,42–45]. There is
increasing evidence that this pathway is abnormally regu-
lated in HCC and other cancers and plays a central role in
tumorigenesis and maintenance of tumor growth [17,19,46].
Treatment strategies targeting p42/p44 MAPK signaling inter-
mediates such as MEK, therefore, have significant merit [37,
43,47,48]. This study examined the effects of PD184161, a
novel, high-affinity, orally active MEK inhibitor, on p42/p44
MAPK signaling, proliferation, apoptosis, tumor engraftment,
and early and established tumor growth in human HCC.
PD184161, which is structurally distinct from PD098059
and U0126, joins this mechanistic class of agents that inhibit
the downstream phosphorylation of ERK through their direct
effects on MEK [40,47,49]. PD098059 prevents the activa-
tion of MEK1, whereas U0126 appears to inhibit the acti-
vation of MEK through Raf, but also the downstream
phosphorylation of ERK by activated MEK [40,50]. Here we
report that PD184161 significantly inhibits p42/p44 MAPK
signaling in human HCC cell lines, as evidenced by the in-
hibition of downstream ERK1,2 phosphorylation. PD184161,
compared to PD098059, resulted in greater suppression of
signaling and was superior to or equally effective as U0126.
The effectiveness of U0126 is likely linked to its significantly
higher affinity for MEK than PD098059 [40]. PD184161 is
believed to share this enhanced affinity for MEK, but unlike
PD098059 and U0126, PD184161 has the obvious advan-
tages of solubility and oral bioavailability. The pharma-
cological potential of targeting MEK capitalizes on the
overexpression and dependence of tumor cells on the p42/
p44 MAPK activation for cell survival. A normal liver has al-
most undetectable levels of p42/p44 MAPK activity com-
pared to high levels of p42/p44 MAPK activity in human HCC
[19]. This significant difference in activity makes the regional
delivery of p42/p44 MAPK-targeted treatments seem very
feasible. Because this pathway has important effects in nor-
mal cellular functions, the systemic delivery of MEK-targeted
agents may have untoward effects. Clinical trials with CI-
1040, a structurally related analog of PD184161, in breast
cancer, colon cancer, non–small cell lung cancer, and pan-
creatic cancer did not show sufficient antitumor activity to
continue the trials; however, significant systemic toxicity
was not found to be an issue with this drug [51]. A second-
generation MEK inhibitor PD0325901 has recently shown
promise in clinical trials for the treatment of melanoma [52].
By examining the growth of human HCC cell lines follow-
ing treatment with PD184161, we found this compound to
inhibit the growth of these cells in a time- and concentration-
dependent manner, which appears to correlate with suppres-
sion of p42/p44 MAPK signaling. In a related study, Huynh
et al. [17] recently reported that overexpression of MEK1 in
transfected HepG2 cells resulted in resistance to apoptosis
caused by U0126 treatment, demonstrating the connection
between MEK activity and MEK-targeted treatments. Al-
though the efficacy of PD098059 and U0126 as inhibitors
of in vitro cell growth and promoters of apoptosis has been
documented in our laboratory and others [17,53], the experi-
ments reported here indicate that PD184161 is more effec-
tive in vitro and has the distinct advantage of also being
effective in vivo.
MEK-targeted treatment has been studied in colon and
breast tumors [54–56], but the use of small molecule MEK
inhibitors in human HCC tumors, to our knowledge, has not
been examined. TargetingMEKwith PD184161 in vivo resulted
in a significant delay in HCC tumor engraftment and inhibi-
tion of early tumor growth. MEK-transfected HepG2 cells have
been shown to growmore rapidly in vivo thanmock-transfected
HepG2 cells, linking HCC growth to MEK activity [17].
In contrast, PD184161 was ineffective at suppressing es-
tablished HCC tumor growth. In addition, MEK suppression
by PD184161 was not achieved in tumors ‘‘conditioned’’ by
multiple doses of the drug, but only in ‘‘naı¨ve’’ tumors that
had received a single drug dose. The systemic efficacy of
PD184161 is unlikely to be responsible for the lack of drug
effectiveness because the lung, an organ expressing high
MEK activity, was effectively suppressed with PD184161
treatment after repeated dosing. It is possible that organ-
specific bioavailability (lung versus tumor), tumor vascular-
ity, or P-glycoprotein expression could be involved in our
Figure 7. The effect of single and multiple oral dosing with the MEK inhibitor PD184161 on the expression of phosphorylated ERK1,2 (A) and total ERK1,2 (B) in
nude mouse Hep3B tumor xenografts and lung. Homogenates from Hep3B tumors were prepared from treated and control mice and assessed by Western blot
analysis for phosphorylated ERK1,2 and total ERK1,2 levels. Representative Western blot analyses are shown here. Results were reproducible in multiple assays.
Densitometric analysis was performed, and results were analyzed by t-test (P < .05).
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observations, and these issues may be the subject of future
study. Although Hep3B cells do not harbor Ras or Raf mu-
tation, the growth of this cell line responds to MEK inhibition
in vitro; importantly, early Hep3B tumor growth in vivo is de-
layed by PD184161 treatment. Although we have not estab-
lished a causal link between the lack of P-ERK signal
suppression in the long-term dosing of PD184161 and the lack
of effect on established tumor growth, we cannot exclude the
possibility that effective MEK inhibition, if achieved, would
reduce HCC tumor growth. In this investigation, the lack of
growth inhibition appears to correlate with the lack of suppres-
sion of P-ERK level, which was the target of PD184161. How-
ever, other signaling pathways could be involved in the growth
of these tumors. Not all tumor types behave in this fashion. Our
coauthor reported tumor growth reduction and concomitant re-
duction in MEK activity in established colon tumor xenografts
after treatment with CI-1040, a structurally related analog of
PD184161 [55]. Melanoma and lung cancer also appear to
be similarly susceptible [55,57,58]. Thus, HCC appears to
be unique in its ability to develop resistance to PD184161.
The study of chemoresistance of HCC tumors to small mole-
cule inhibitor treatment is an extremely important but relatively
untapped field of investigation. Understanding the novel resis-
tance mechanism of HCC to MEK-targeted treatment may
have broader implications and may shed light on mechanisms
of small molecule inhibitor resistance in other systems.
In summary, we have shown that a novel, highly specific
MEK inhibitor PD184161 more effectively suppresses MEK
activity in multiple HCC cell lines when compared to MEK
inhibitors PD098059 and U0126. Its efficacy as an inhibitor
of HCC cell proliferation and promoter of apoptosis corre-
lates with its observed effects on MEK activity. Importantly,
in vivo, PD184161 successfully inhibits tumor engraftment
and early growth of human HCC xenografts. Growth of es-
tablished tumors, however, was not significantly affected by
PD184161. Correspondingly, MEK activity in human tumors
was suppressed with PD184161 initially, but not with longer-
term administration. MEK remains an intriguing chemother-
apeutic target for the treatment of human HCC; however,
the degree of success of MEK-targeted treatment in HCC
and other cancers may depend, in part, on the discovery of
mechanisms governing MEK inhibitor signaling resistance.
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